Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 8Recruiting 7Active not recruiting 3Unknown 2Not yet recruiting 2Withdrawn 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 2Wounds and Injuries 1Trauma, Nervous System 1Stress Disorders, Post-Traumatic 1Depressive Disorder, Major 1Depression 1

Interventions

Cisplatin 504Cyclophosphamide 353Radiotherapy 349Carboplatin 347Capecitabine 328Oxaliplatin 319Paclitaxel 316Gemcitabine 315Docetaxel 308Fluorouracil 281apatinib 240Drug Therapy 239Bevacizumab 224camrelizumab 212Etoposide 199Irinotecan 176Doxorubicin 174Dexamethasone 159Leucovorin 158sintilimab 140Pemetrexed 136Cytarabine 136pembrolizumab 135anlotinib 135toripalimab 124S 1 (combination) 119Neoadjuvant Therapy 119Vincristine 118Rituximab 114Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Interventional × Psilocybin × Clear all
NCT05042466 2022-11-16

NWTTPS

NWTraumatherapies

Phase 1 Unknown
30 enrolled

Depression, Neoplasms, Stress Disorders, Post-Traumatic, Wounds and Injuries, Trauma, Nervous System

NCT04593563 2021-10-15

The Safety and Efficacy of Psilocybin in Cancer Patients With Major Depressive Disorder

Maryland Oncology Hematology, PA

Phase 2 Unknown
30 enrolled

Depressive Disorder, Major, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡